VAERS Explorer
Back to explore

Report #2891642

Received Apr 3, 2026

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex
Female
Age
68 yrs
State
TX
Recovered
Not recovered
Vaccinated
Mar 25, 2026
Onset
Mar 26, 2026
Days to onset
1
Hospital days

Vaccines (1)

TypeNameManufacturerDoseLotRoute / Site
COVID19COVID19 (COVID19 (MODERNA MNEXSPIKE))MODERNAUNK3052155IM

Symptoms (6)

Body temperatureFatigueHeadachePeripheral swellingPyrexiaRash

Symptom narrative

rash; severe headache; fatigue; fever; arm swelling/swelling; This spontaneous case was reported by a consumer and describes the occurrence of PERIPHERAL SWELLING (arm swelling/swelling), RASH (rash), HEADACHE (severe headache), FATIGUE (fatigue) and PYREXIA (fever) in a 68-year-old female patient who received mRNA-1283 (MNEXSPIKE PFS) (batch no. 3052155) for COVID-19 prophylaxis. The suspect product included Pre-filled Syringe injection (batch no. 3052155) for COVID-19 prophylaxis. Previously administered products included for COVID-19 prophylaxis: MNEXSPIKE PFS (Dose 1) on 08-Sep-2025. Past adverse reactions to the above products included No adverse effect with MNEXSPIKE PFS. On 25-Mar-2026, the patient received dose of mRNA-1283 (MNEXSPIKE PFS) (Intramuscular use) 1 dosage form. On an unknown date, the patient started Pre-filled Syringe (unknown route) at an unspecified dose. On 26-Mar-2026, the patient experienced PERIPHERAL SWELLING (arm swelling/swelling), HEADACHE (severe headache), FATIGUE (fatigue) and PYREXIA (fever). On 27-Mar-2026, the patient experienced RASH (rash). On 27-Mar-2026, PYREXIA (fever) had resolved. At the time of the report, PERIPHERAL SWELLING (arm swelling/swelling), RASH (rash), HEADACHE (severe headache) and FATIGUE (fatigue) was resolving. DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 26-Mar-2026, Body temperature: 101 degree Fahrenheit. Concomitant medication was not provided. It was reported that within 12 hours of vaccination, patient developed a fever. She also experienced other symptoms which interfered with her ability to perform daily activities. On the third day, she developed a rash along with the swelling and a picture was provided. It was stated that none of these symptoms had occurred following her previous dose of mNEXSPIKE administered on 08-Sep-2025. It was unknown if the patient experienced any additional symptoms or events. Treatment medication was not reported.; Reporter's Comments: The benefit-risk relationship of product is not affected by this report.

Lab data

Test Date: 20260326; Test Name: body temperature; Result Unstructured Data: 101 degree Fahrenheit

Report #2891642 · VAERS Explorer